For instance, KRAS-driven tumors have been associated with neutrophil-rich inflammation and distinct metastatic behavior, while EGFR-mutated neoplasms frequently display “cold” immune phenotypes, characterized by low PD-L1 expression and reduced sensitivity to checkpoint blockade [13]. The gene discussed is KRAS; the disease is neoplasm.